Canatu (CANATU) investor relations material

Strategic Vision and Business Model Evolution

• Transitioning from technology validation to scalable value creation, leveraging a unique carbon nanotube (CNT) platform for global relevance in semiconductors, automotive, and medical diagnostics.

• Focused execution and disciplined capital allocation prioritize high-value, scalable applications, with semiconductors as the primary growth driver.

• Employs asset-light business models: reactor/licensing for high-integration, high-volume applications, and direct product sales for high-value, lower-volume segments, enabling flexibility and recurring revenue.

• Competitive edge built on proprietary Dry Deposition™ technology, over 300 patents, and deep customer integration, creating high switching costs and strong barriers to entry.

• New business development follows a disciplined, partner-led, milestone-driven approach, leveraging public funding and targeting 2–5 new product families by 2030.

Market Opportunities and Technology Positioning

• Semiconductor: AI-driven demand and EUV lithography adoption fuel CNT pellicle scaling, with inflection points at 2.0nm and 1.4nm nodes between 2026–2029.

• Automotive: Electrification and autonomous driving drive demand for CNT-based ADAS camera heaters, windshield heaters, and solar cells, with partnerships (e.g., DENSO) supporting scale-up.

• Medical diagnostics: Shift to point-of-care testing for hormone and sepsis diagnostics, with CNT-based sensors enabling rapid, cost-effective results and commercial launches planned by 2030.

• Advanced CNTs command a value premium over bulk CNTs, with applications in high-margin, high-growth domains.

• Roadmap includes alpha/beta prototypes, clinical trials, and mass production milestones for new products by 2030.

Financial Targets and Growth Outlook

• 2030 targets: €100–150M revenue and 25–30% EBIT margin, with semiconductors expected to deliver the largest share and recurring revenues exceeding 50% of total.

• Revenue growth in medical diagnostics and new business development expected to accelerate toward the end of the strategic period, though from a smaller base.

• CapEx will peak in 2026 at €14–18M due to facility investments, then stabilize at €5–6M annually; headcount growth of 10–35 FTEs per year anticipated.

• Financial model is built bottom-up, with recurring revenues from royalties, consumables, and services becoming predominant by 2030.

• Gross margins projected to remain strong (over 70% in 2025), supported by high barriers to entry and pricing power.